BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
2 O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23 Suppl 1:e12519. [PMID: 30203585 DOI: 10.1111/hel.12519] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
3 Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. Helicobacter. 2018;23:e12502. [PMID: 29924430 DOI: 10.1111/hel.12502] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
4 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
7 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]